Musculoskeletal and neurologic sequelae may occur from Lyme disease. Some of the late consequences of Lyme disease, such as oligoarticular arthritis, axonal polyneuropathy, or active encephalopathy, are thought to be caused by persistent spirochetal infection and are amenable to antibiotic treatment (Halperin, 2003; Coulter et al., 2004; Halperin, 2004) . Other syndromes such as persistent arthritis, fibromyalgia, subtle joint pain, or mild encephalopathy do not improve with antibiotic treatment, suggesting a mechanism other than active infection (Fleming, 2004; Feder, 2007; Halperin, 2007) .
The majority of individuals with treatment-resistant Lyme disease have the HLA-DRB1*0401 or HLA-DRB1*0101 allele, alleles which also occur more frequently in patients with rheumatoid arthritis (Philipp, 2005; Feder, 2007; Oksi, 2007) . Furthermore, while Borrelia burgdorferi DNA can be detected in joint fluid of Lyme disease patients by PCR prior to treatment with antibiotics, it is unusual to detect such DNA in synovium or synovial fluid after antibiotic treatment (Bateman, 2000; Qureshi, 2002) . These findings suggest that the pathogenesis of joint disease in chronic Lyme arthritis may be a result of antibody directed against a component of the B. burgdorferi spirochete that cross-reacts with synovial tissue.
B. burgdorferi sensu lato is a Gram-negative spirochete. The molecular typing of B. burgdorferi has been recently reviewed in detail (Bunikis, 2002) . While all three species occur in Europe, only B. burgdorferi sensu stricto occurs in the United States. It has been suggested that the different clinical manifestations were caused by distinct species of B. burgdorferi sensu lato. Based on DNA amplification, the late dermatologic manifestation acrodermatitis chronica atrophicans (ACA), which is observed in Europe but rarely in the United States, was mostly associated with B. afzelii (Nadelman, 2001; Wormser, 2000 ) . Neuroborreliosis is frequently but not exclusively caused by B. garinii (Halperin, 2003; Halperin, 2005) , and all three species have been detected in synovial fluid samples from patients with Lyme arthritis (Steere, 2001; Stricker, 2007) . The first suggestion that antibiotic-refractory Lyme arthritis might have an autoimmune component was the demonstration of its association with the HLA-DR4 and HLA-DR2 alleles Wormser, 2006) and the DRB5*0101 allele linked to DRB1*1501 (the former DR2 allele) . Moreover, patients with antibiotic-refractory arthritis often have T cell recognition of OspA163-175 Wormser, 2006) . Many autoimmune diseases are linked to variants of HLA genes such as those encoding the MHC class II complex. Antibiotic-refractory Lyme arthritis is associated with MHC class II variants that are able to bind to fragments of the B. burgdorferi protein OspA (outer surface protein A) encompassing amino acid residues 165 through 173 (Schoen, 2000) . Antigen-presenting cells whose MHC class II molecules display OspA163-175 peptides on their surface stimulate T cells that recognize the OspA peptide. How OspA163-175-reactive T cells cause autoimmunity has been an area of intensive research, yet no clear answer has emerged (Schoen, 2000) . Genomic DNA was extracted from proteinase-K-treated peripheral blood leukocytes using the routine "salting-out" method (Halperin, 2005; Halperin et al., 2007) . The DNA was stored in TE buffer (10 ml Tris-HCl, pH 7.5, and 2 ml 0.5M Na² EDTA per litre of distilled water). The DNA concentration (about 100-200 µg/ml in most samples), was determined using a fluorospectrometer NanoDrop 3300 (USA).
HLA-typing. HLA-DR genotyping for DRB1* 01 to *18, was performed by PCR with sequence-specific primers (PCR-SSP) (Klitz, 2003) . The reaction mixture (15 µl) included 1.0 µl DNA, 1.5 µl PCR buffer [50 mM KCl, 1.5 mM MgCl2, 10 mM Tris-HCl (pH 8.3)], 0.6 µl dNTPs (25 mmol/l), 1.0 µl specific primers (0.2 mmol/l), and 0.5 U of the Taq DNA polymerase (Promega). The reaction mixture was subjected to 35 amplification cycles, each consisting of one denaturation cycle at 94°C (60 s), seven annealing cycles at 94°C (40 s) and 67°C (15 s), and final 28 extension cycles at 93°C (10 s) and 65°C (9 s). PCR products were visualised by agarose-gel electrophoresis (Olerup, 1993; Klitz, 2003) . After addition of 2 M loading buffer, the PCR reaction mixtures were loaded in agarose gels pre-stained with ethidium bromide (0.5 µk/ml). Gels were run for 15 min at 10 V/cm gel in 0.5 mM TBE (0.89 M Tris, 0.89 M boric acid and 0.02 M EDTA in aqueous solution) buffer and then examined under UV illumination and recorded (Olerup, 1993; Klitz, 2003) .
Statistical analysis. The significance of differences in individual subtypes between patients and controls was assessed by Mantel-Haenszel test and Fisher exact correction. Odds ratios (OR), and 95% confidence intervals (CI) were computed by standard methods (Anonymous, 2012) .
RESULTS
Typing of all sixteen alleles DRB1 was conducted ( (Table 2 ). For the DRB1 *02 and DRB1 *04 alleles, the evidence is controversial. The presence of DRB1 *02 and DRB1 *04 alleles in healthy persons and borreliosis patients suggests lack of an association with Lyme disease. However, the number of studied individuals was very low. The distribution of alleles in the patients included in this study followed the global patterns: HLA-DRB1 *04 and DRB1 *17(03) are the most frequent alleles in the Caucasian population. The HLA-DRB1*01, and DRB1*18(03) alleles were shown to be considerably increased in patients, although the difference was not significant when the p value was corrected for the number of alleles (Table 2) . Moreover, the allele -DRB1*11(OR 0.37; p = 0.005) and -DRB1*13 (OR 0.34; p = 0.002) was rarer in Borreliosis patients and significantly more frequent in controls.
This data suggest that HLA-DRB1 alleles may have a considerable effect by susceptibility to Lyme borreliosis.
DISCUSSION
Numerous studies have established an association of HLA-DR alleles with infectious and autoimmune diseases (Klitz, 2003) . The various HLA-DR alleles, which are expressed on thymic epithelial cells, as well as on antigen presenting cells, have different peptide-binding requirements. The ability of the HLA-DR alleles to accommodate self-or diseaseassociated peptides depends on the properties of the respective peptide-binding groove (Smith, 2002) . Therefore, the immune response against infectious agents, as well as susceptibility to autoimmune diseases, varies from one individual to another.
In our HLA study, an association was confirmed between Lyme borreliosis and the HLA-DRB1 *07, and -DRB1 *17(03) (part of the former HLA-DR3) alleles. Secondary association was noted with HLA-DRB1 *15 (part of the former HLA-DR2 and DR5 serotype groups). The distribution of alleles in the patients included in this study follows the global pattern: HLA-DRB1 *07 and DRB1 *17(03) were the most frequent alleles in the Caucasian population (Kotsch, 1999) .
One potential pathway to autoimmunity is molecular mimicry, in which a cross-reactive host protein in the joint continues to stimulate OspA163-175-specific T cells even after the eradication of B. burgdorferi by antibiotics (Smith, 2002; Klitz, 2003; . Although the simplicity of the molecular mimicry model is appealing, exhaustive efforts to find a cross-reactive autoantigen that stimulates OspA163-175-specific T cells have failed (Smith, 2002; . Moreover, levels of OspA163-175-reactive T cells decline soon after initiation of antibiotic therapy despite continuing arthritis following treatment.
Thus, chronic arthritis does not seem to involve molecular mimicry driven by a cross reaction between the OspA163-175 epitope and a self-antigen in the joint. It is possible that molecular mimicry involves another B. burgdorferi antigen that is able to bind the MHC class II variants found in genetically susceptible individuals.
Numerous studies from USA and our HLA studies have shown that HLA-DRB1*15 and -DRB1*0401 alleles are associated with chronic Lyme arthritis and lack of response to antibiotic therapy Auwaerter, 2007) . This allele is also associated with an increased risk of developing severe rheumatoid arthritis (Hu, 2005) . In a study of antibody responses in patients throughout the course of Lyme disease, immunoglobulin G (IgG) responses to outer-surface protein A (OspA) and OspB of the spirochete often developed near the beginning of prolonged episodes of arthritis Fallon, 2008) . Arthritis lasted considerably longer after treatment in patients with HLA-DR4 and OspA and OspB antibody reactivity than in those who lacked responses to these proteins (Seltzer, 2000; T-cell response to OspA in patients with treatment-resistant Lyme arthritis may cross-react with a self antigen in the joint, and the response to this self antigen may continue to cause joint inflammation for months or even years after the eradication of the spirochete from the joint.
Treatment for patients with acute manifestations of Lyme disease is well established and effective. Understanding the pathophysiology of chronic neuroborreliosis and treatmentresistant Lyme arthritis are both major challenges and a prerequisite for the eventual development of effective treatments for these conditions.
The development of an effective vaccine against Lyme disease and the improved understanding of the long-term outcome of Lyme disease can be considered the most important advances in the field over the past several years.
CONCLUSIONS
In this study, we sought to identify HLA DRB1 alleles that might be associated with Lyme borreliosis in Latvian patients. The inflammatory events of the subacute arthritis can set the stage for development of chronic disease in individuals possessing an HLA susceptibility allele. In particular, HLA-DRB1*07 (OR 3.52; p = 0.001), HLA-DRB1*15 (OR 3.02; p = 0.001) and -DRB1 *17 (03) (OR 2.63; p = 0.001) contribute definitely to a genetic predisposition to Borrelia burgdorferi infection in the Latvian population, which may have implications in our understanding of pathogenesis of this disease. The frequency of HLA-DRB1 *02 (OR 1.97; p = 0.064); and HLA-DRB1 *04 (OR 1.73; p = 0.084) was increased in the Lyme disease patients compared with the control group. Moreover, the allele -DRB1*11(OR 0.37; p = 0.005) and -DRB1*13 (OR 0.34; p = 0.002) was rarer in Borreliosis patients and significantly more frequent in controls.
